These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Plasma interleukin-18/interleukin-18 binding protein ratio in Chinese with NAFLD. Author: Li Y, Li-Li Z, Qin L, Ying W. Journal: Hepatogastroenterology; 2010; 57(97):103-6. PubMed ID: 20422882. Abstract: BACKGROUND/AIMS: The liver has been recognized as a major target of injury in patients with metabolic syndrome and non-alcoholic fatty liver disease has even been considered the hepatic manifestation of metabolic syndrome. Pathogenesis of non-alcoholic fatty liver disease remained unclear. Interleukin-18 belonged to pro-inflammatory cytokines and previous studies showed plasma levels of interleukin-18 correlated with metabolic syndrome. There has been no report regarding plasma levels of interleukin-18 in Chinese patients with non-alcoholic fatty liver disease. METHODOLOGY: A total of 46 non-alcoholic fatty liver disease patients and 46 age- and sex-matched control subjects were enrolled to compare the clinical and laboratory characteristics and plasma levels of interleukin-18, interleukin-18 binding protein, and interleukin-18/interleukin-18 binding protein ratio. Interleukin-18 and interleukin-18 binding protein were determined by commercially available enzyme-linked immunosorbent assay (Bender MedSystem, Austria, R&D Systems, Minneapolis, MN, USA, respectively). RESULTS: As compared with control group, patients with non-alcoholic fatty liver disease had significantly higher body mass index (p < 0.001), waist circumference (p < 0.001), total cholesterol (p = 0.001), triglyceride (p < 0.001), low-density lipoprotein cholesterol (p = 0.002), fasting sugar (p = 0.042), fasting insulin (p < 0.001), homeostasis model assessment of insulin resistance index (p < 0.001), and lower high-density lipoprotein cholesterol (p = 0.006). Patients with non-alcoholic fatty liver disease had significantly higher interleukin-18 (340.10 +/- 43.13pg/mL) and interleukin-18/ interleukin-18 binding protein ratio (1.31 +/- 0.12) compared with control group. Nonalcoholic fatty liver disease patients with abnormal alanine aminotransferase had higher plasma interleukin-18 (352.60 pg/mL) than non-alcoholic fatty liver disease patients with normal alanine aminotransferase but did not reach the statistical differences. CONCLUSIONS: Through the chemotactic and proinflammatory effects, interleukin-18 may play a role in the pathogenesis of non-alcoholic fatty liver disease in Chinese patients, and it is reasonable to take into account interleukin-18 binding protein when evaluating the effect of interleukin-18.[Abstract] [Full Text] [Related] [New Search]